27

28

DECLARATION OF EDWARD O. GRAMLING

I, Edward O. Gramling, declare, pursuant to 28 U.S.C. § 1746, as follows:

- 1. I am employed by Pfizer, Inc. ("Pfizer") as an Assistant General Counsel. I have personal knowledge of the matters set forth below and, if called as a witness, would testify to these facts under oath.
- 2. I make this declaration at the request of the United States Securities and Exchange Commission ("SEC").
 - 3. Pfizer is a research-based, global pharmaceutical company.
- 4. On or about February 8, 2018, the SEC requested that Pfizer provide it with certain information concerning companies called Titanium Blockchain Infrastructure Services, Inc. ("TBIS") and EHI Internetwork and Systems Management, Inc. ("EHI"), and an individual named Michael Stollaire aka Michael Stollery or Michael Stoller ("Stollaire").
- 5. In my capacity as an Assistant General Counsel of Pfizer, I am required, periodically and as needed, to become familiar with the entities with which Pfizer has contracts, agreements, and/or other substantive business relationships including alliances and partnerships. In addition, in my capacity as an Assistant General Counsel of Pfizer, I share responsibility with other members of the Pfizer's legal department, intellectual property counsel, and others to protect Pfizer's trade name, trademarks, and service marks from infringement and other unauthorized uses by third parties. In response to the SEC's request, and at my direction, Pfizer's personnel reviewed the books, records, files, and computer systems of the business units within Pfizer that might reasonably be expected to have or to have had any type of business relationship with TBIS or EHI or Stollaire including as a customer, client, vendor, employee, contractor, consultant, or other type of business transaction.
- 6. Pfizer keeps and maintains business records in the course of its transactions and regularly conducted activities as a regular practice. It is Pfizer's practice to prepare such records at or near the time of the occurrence of the matters

set forth by, or from information transmitted by, a person with knowledge of those matters. Pfizer maintains books and records of entities and persons with which it has contracts, agreements, and/or other substantive business relationships, such the purchase and sale of a product or service, making an investment, or entering into an alliance or partnership, including authorized uses by third parties of its trade name, trademarks, and service marks. Pfizer also maintains books and records of entities and persons with which it has engaged as an employee, vendor, contractor, or consultant. For the purposes of this declaration, as an Assistant General Counsel of Pfizer, I am the custodian of those records or am otherwise qualified to testify about them.

- 7. Pfizer's books and records are current as of the date of this declaration. The search of these materials has not disclosed any current or past business relationship of any kind between Pfizer and TBIS or EHI or Stollaire directly.
- 8. The search of these materials indicates that Pfizer used the services of Accenture, as a third party contractor, to provide certain information technology ("IT") services to Pfizer and that Stollaire worked on the IT services between April 26, 2016 and November 30, 2016 at which time Stollaire's involvement ceased. These materials indicate the scope of the IT services involved commercially available IT products and services used by Pfizer, and did not include blockchain technology or digital currency.
- 9. The search of these materials has not disclosed that Pfizer has ever authorized TBIS or EHI or Stollaire to use Pfizer's name or logo in their marketing or advertising. Pfizer's name and logo are the intellectual property of the company. Pfizer considers a third-party's unauthorized use of the "Pfizer" name or logo in marketing or advertising as an infringement of its intellectual property.
- 10. Pfizer sent Stollaire a cease and desist letter on March 15, 2018, a true and correct copy of which is attached hereto as Exhibit 1.

11. On March 19, 2018 we received a response from Mr. Stollaire which is attached as Exhibit 2.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

Executed this 20th day of March, 2018 at New York, New York

Edward O. Gramling

EXHIBIT 1

Arnold Porter

Paul C. Liewellyn +1 212.836.7828 Direct Paul.Liewellyn@arnoldporter.com

March 15, 2018

VIA FEDEX

Mr. Michael Stollaire Titanium Blockchain Infrastructure Services, Inc. 15027 Dickens Street, Suite 4 North Hollywood, CA 91403

Mr. Michael Stollaire EHI-INSM Inc. 15027 Dickens Street, Suite 4 North Hollywood, CA 91403

Re: Unauthorized Use of the PFIZER® Trademarks and Logos by Michael Stollaire, Titanium Blockchain Infrastructure Services, Inc., and EHI-INSM Inc.

Dear Mr. Stollaire:

We write on behalf of our client Pfizer Inc. ("Pfizer") with regard to your unauthorized use of Pfizer's valuable trademarks and logos. In particular, it has come to our client's attention that you have used, without authorization, the federally-registered PFIZER trademark and logo on the websites for both Titanium Blockchain Infrastructure Services, Inc. ("Titanium Blockchain") and EHI-INSM Inc. ("EHI"), and have falsely asserted that Pfizer has been a client of your companies' services, as shown in the webpages attached as Exhibit A.

As you are undoubtedly aware, Pfizer Inc. is one of the world's largest pharmaceutical manufacturers and sellers and maintains global operations in more than 150 countries. Pfizer owns numerous federal trademark registrations for the mark PFIZER, including U.S. Trademark Registration Nos. 626088, 2951026, 3932037, 3125531 and 5082880, covering both the word mark PFIZER and the stylize "PFIZER" oval logo. Pfizer's federal registrations covering these marks include without limitation the following:

Arnold Porter

Mr. Michael Stollaire March 15, 2018 Page 2

U.S. REG. NO.	MARK	REG. DATE
0626088	Pfizer	May 1, 1956
3125531	Pfizer	August 8, 2006
3932037	Pfizer	March 15, 2011
2951026	PFIZER	May 17, 2005
4245996	PFIZER	November 20, 2012
5082880	PFIZER	November 15, 2016
3114047	PFIZER BRIDGE PROGRAM	July 11, 2006
4593658	PFIZER RXPATHWAYS	August 26, 2014
4018192	PFIZER INJECTABLES	August 30, 2011
5157646	PFIZER CENTERONE	March 7, 2017

Pfizer uses these extremely well-known marks in connection with the sale of a wide variety of pharmaceutical products and consumer healthcare products. Pfizer has expended millions of dollars to promote these marks, and has achieved billions of dollars of sales under the marks. As a result of the extensive use of the marks in advertising and the enormous sales success under those marks, the marks have become closely associated by the public with Pfizer, which owns strong trademark rights in these marks, has developed an excellent reputation for its products and services offered under the marks, and has garnered substantial goodwill in the marks.

Notwithstanding Pfizer's strong rights in the PFIZER word mark and logo described above, your companies have reproduced these marks to promote your services, by listing Pfizer and using the PFIZER logo among various companies that purportedly are clients of your companies. On the Titanium Blockchain website, a recent version of the "About Us" page at this.io/about-us/ (see Exhibit A) displayed the PFIZER logo among a group that the website claims are "some of EHI's customers." On the EHI website, the Pfizer logo is among the first to appear under a page titled "Our Clients".

We note that the this, io website is currently "under construction." We demand that the company refrain from any reference to Pfizer or its marks on any new or revised pages at this website.

Arnold Porter

Mr. Michael Stollaire March 15, 2018 Page 3

Pfizer has never engaged Titanium Blockchain, EHI, or Michael Stollaire, nor has it in any way authorized any use of its name or logo by them. Accordingly, these references to Pfizer and these uses of the PFIZER name and logo constitute false representations in commercial advertising, and are very likely to cause confusion among prospective purchasers as to the association, endorsement or approval of your companies' services by Pfizer, and to cause prospective purchasers to mistakenly believe that Pfizer has in fact retained these companies' services, all of which is false. Under these circumstances, confusion and a false understanding among prospective purchasers are not only likely, but are inevitable. Further, the use of the Pfizer logos in this manner inevitably dilutes the distinctive nature of these famous marks. Accordingly, the foregoing conduct constitutes, among other things, trademark infringement and dilution, false designation of origin, false endorsement, false association, false advertising and unfair competition in violation of the federal Lanham Act, 15 U.S.C. §§ 1114, 1125(a) and 1125(c), and state law.

Your actions described above are a matter of great concern to Pfizer, which has spent significant sums of money and considerable effort developing its valuable trademark rights and is committed to protecting those rights. Pfizer requests that, within five days of the receipt of this letter, you cease and desist from all use of the PFIZER mark and logo and all other references to Pfizer in connection with your companies and businesses, including without limitation on the websites described above as well as in all other forms of advertising, marketing and promotion, and agree to refrain in the future from any such uses of Pfizer's marks and references to Pfizer.

We trust that you will appreciate the seriousness of this matter and will act immediately to comply with the foregoing requests, so that this matter can be put to rest.

Very truly yours,

Paul C. Llewellyn

PCL:ms Attachment

Exhibit A



We have raid the planter to of working with global leaders in various industries. Our ITM approach to solving prising a problems with IT. specification of the second second second second representations of the second representation of the second residence of the s oak at what some of our clients have sale.









EXHIBIT 2



orter

Paul C. Llewellyn +1 212.836.7828 Direct Paul.Llewellyn@arnoidporter.com

WE ARE THE REVOLUTION.

VIA FEDEX

Mr. Michael Stollaire Titanium Blockchain Infrastructure Services, Inc. 15027 Dickens Street, Suite 4 North Hollywood, CA 91403

Mr. Michael Stollaire EHI-INSM Inc. 15027 Dickens Street, Suite 4 North Hollywood, CA 91403

Re: Unauthorized Use of the PFIZER® Trademarks and Logos by Michael Stollaire, Titanium Blockchain Infrastructure Services, Inc., and EHI-INSM Inc.

Dear Mr. Stollaire:

We write on behalf of our client Pfizer Inc. ("Pfizer") with regard to your unauthorized use of Pfizer's valuable trademarks and logos. In particular, it has come to our client's attention that you have used, without authorization, the federally-registered PFIZER trademark and logo on the websites for both Titanium Blockchain Infrastructure Services, Inc. ("Titanium Blockchain") and EHI-INSM Inc. ("EHI"), and have falsely asserted that Pfizer has been a client of your companies' services, as shown in the webpages attached as Exhibit A.

As you are undoubtedly aware, Pfizer Inc. is one of the world's largest pharmaceutical manufacturers and sellers and maintains global operations in more than 150 countries. Pfizer owns numerous federal trademark registrations for the mark PFIZER, including U.S. Trademark Registration Nos. 626088, 2951026, 3932037, 3125531 and 5082880, covering both the word mark PFIZER and the stylize "PFIZER" oval logo. Pfizer's federal registrations covering these marks include without limitation the following: